Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12269958 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2NPSR1SSTR4GRIA4HPGD | |
| SCHEMBL27827576 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NPSR1SSTR4GRIA4HPGD | |
| SCHEMBL27827577 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NPSR1SSTR4GRIA4HPGD | |
| SCHEMBL9518166 | 0.83 | SSTR4 (0.56) | SMN1; SMN2NPSR1SSTR4GRIA4HPGD | |
| SCHEMBL9518171 | 0.83 | SSTR4 (0.56) | SMN1; SMN2NPSR1SSTR4GRIA4HPGD | |
| SCHEMBL15591888 | 0.83 | SSTR4 (0.67) | SMN1; SMN2NPSR1SSTR4GRIA4HPGD | |
| SCHEMBL25021708 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1KDM1AMTNR1AMTNR1B | |
| SCHEMBL1197466 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1KDM1AMTNR1AMTNR1B | |
| SCHEMBL862934 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1KDM1AMTNR1AMTNR1B | |
| SCHEMBL13794162 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2NPSR1KDM1AMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344004-B2 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-01-01 | — | — | US | disclosed |
| EP-2240474-B1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-03-14 | — | — | EP | disclosed |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-09-15 | — | — | US | disclosed |
| CN-101910162-A | Cyclic pyridyl-N- [1,3,4] -thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI AVENTIS | 2010-12-08 | — | — | CN | disclosed |
| EP-2240474-A1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009080223-A1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | PPARD, PPARG, PPARA | SMN1; SMN2 225/4885NPSR1 2126/4885SSTR4 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.